Trivalent Influenza Virus Subunit Vaccine (Adjuvanted)
We are also developing an investigational trivalent influenza virus subunit vaccine (adjuvanted). Its mechanism of action, formulation process and manufacturing technology are similar to those of the investigational quadrivalent influenza virus subunit vaccine (adjuvanted), with the only difference being that one influenza B virus subtype (Yamagata) is omitted during the formulation process. We obtained the Investigational New Drug (IND) approval for the investigational trivalent influenza virus subunit vaccine (adjuvanted) in October 2024, and it is expected to initiate Phase I clinical trials in the fourth quarter of 2025.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
ONLINE
NEW PRODUCTS
Need more help?
Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.
CONTACT
- E-Mail: yue.peng@yitherbiotech.com
- Hotline: +86-021-61639751
- Address: No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai
SHARE
Copyright: Yither Biotechnology Co. Ltd Powered by:www.30.cn SEO
